by npugar | Feb 9, 2022 | Uncategorized
Dr. Kenneth Pugar Dr. Kenneth Pugar recently submitted this editorial to the Dayton Daily News on the CMS draft decision that effectively denies Medicare coverage of FDA-approved medications for Alzheimer’s disease unless the person is enrolled in an approved clinical...
by npugar | Jun 22, 2021 | Uncategorized
DCND is partnering with the Alzheimer’s Association to provide our patients and their families free educational programs during 2021. Registration is required and can be found in the links below. Thursday, July 1, 2021 – 10 Warning Signs of...
by npugar | Jun 10, 2021 | Uncategorized
We still are learning about the new Alzheimer’s drug, Aducanumab (ADUHELM) and its roll out following the FDA’s recent approval. We will continue to update this form as new information becomes available. Dr. Kenneth Pugar discusses new drug here. Who can...
by npugar | Jun 8, 2021 | Uncategorized
DAYTON, OH (DCND) – The Food and Drug Administration has approved the first drug for Alzheimer’s Disease in nearly 20 years. The Biogen drug, Aduhelm (Aducanumab) helps clear a protein linked with Alzheimer’s called beta-amyloid. It’s an...
by npugar | Feb 10, 2021 | Uncategorized
Dayton Center for Neurological Disorders is starting a monthly podcast with the hope of educating patients on Multiple Sclerosis (MS) and its impacts. Every month, a DCND provider will tackle a different topic to help patients manage their disease and live a better...
Recent Comments